Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus

OBJECTIVE: Hydroxychloroquine (HCQ) was not approved in Japan until 2015, and its therapeutic potential has not been explored in depth. We evaluated the additional therapeutic effect of HCQ in Japanese patients with systemic lupus erythematosus (SLE) on maintenance therapy. METHODS: Patients with SL...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Intern Med
Egile Nagusiak: Hanaoka, Hironari, Iida, Harunobu, Kiyokawa, Tomofumi, Takakuwa, Yukiko, Kawahata, Kimito
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Japanese Society of Internal Medicine 2019
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6543229/
https://ncbi.nlm.nih.gov/pubmed/30626831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1999-18
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak